Sutures, staples, clips in wound closure

2 Min Read

Our regular coverage of developments in the field of surgical sealants, hemostasis, wound closure and anti-adhesion, most recently through Report #S180, entails the full potential caseload of patients targeted by these technologies and therefore necessarily encompasses more traditional wound closure methods, such as sutures, staples and clips.

Our regular coverage of developments in the field of surgical sealants, hemostasis, wound closure and anti-adhesion, most recently through Report #S180, entails the full potential caseload of patients targeted by these technologies and therefore necessarily encompasses more traditional wound closure methods, such as sutures, staples and clips.

There is considerable revenue from the sale of these products that is the focus of well established medtech companies.  While sealants, glues, hemostats and other non-traditional wound management products are the thrust of aggressive development by many companies, their ultimate target is largely the market served by traditional wound closure products.

Below is illustrated the number of active companies participating in each of the traditional types of traditional wound closure product segments.

Source: MedMarket Diligence, LLC; Report #S180.

To consider this another way, there are a good number of active companies in these traditional areas, with some predictable ones active in multiple segments.  See this below.

Source: MedMarket Diligence, LLC; Report #S180.

     

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version